Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

CisionPR Newswire_2.png

VANCOUVER, British Columbia and SAN DIEGO, Jan. 16 2019 - We're excited to announce our collaboration with Roche to develop a companion diagnostic (CDx) in TNBC. The Roche/PhoenixMD CDx will measure activated RSK2 in human tumors and will identify patients that will ultimately benefit from our drug PMD-026.

Read the full story on PR Newswire here